Study S001550

Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02119819
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 420
Start: 2014-04
Primary completion: 2015-08
Lead sponsor: OPKO Health, Inc.
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:LY2944876; DRUG:Exenatide extended-release; DRUG:Placebo; DRUG:Metformin
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2013-003552-21; OTHER:I7I-MC-XNAA

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 [Baseline, Week 12]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013400	Emerging PEGylated non-biologic drugs. Park EJ, Expert opinion on emerging drugs	2019	Narrative review	PMID 30957581 DOI	cites ClinicalTrials.gov:NCT02119819; registry reference DERIVED:30957581